Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 1, 2014, Pages 64-76

  Kaikita, Koichi ^a   Ono, Takamichi ^a   Iwashita, Satomi ^a   Nakayama, Naoki ^a   Sato, Koji ^a   Horio, Eiji ^a   Nakamura, Shinichi ^b   Tsujita, Kenichi ^a   Tayama, Shinji ^a   Hokimoto, Seiji ^a   Sakamoto, Tomohiro ^c   Nakao, Koichi ^c   Oshima, Shuichi ^b   Sugiyama, Seigo ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Central Hospital   (Japan)

^c SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

Author keywords

Angina; Coronary artery disease; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; TROPONIN T;

AGED; ARTICLE; BLOOD CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET REACTIVITY; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 84892964677     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.18952     Document Type: Article

References (41)

1. Fuster V, Badimon L, Badimon JJ, Chesebro J: The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med, 1992; 326: 242-250
2. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITONTIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007; 357: 2001-2015
3. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM; TRITONTIMI 38 Investigators: Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a subanalysis of a randomised trial. Lancet, 2008; 371: 1353-1363
4. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF: Cardiovascular death and nonfatal myocardial in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation, 2009; 119: 237-242
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494-502
6. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet, 2001; 358: 527-533
7. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators: Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002; 288: 2411-2420
8. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005; 366: 1607-1621
9. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITYTIMI 28 Investigators: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 2005; 352: 1179-1189
10. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004; 109: 3171-3175
11. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol, 2006; 48: 1742-1750
12. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol, 2005; 46: 1827-1832
13. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ: Cytochrome P450 2C19 681G> A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol, 2008; 51: 1925-1934
14. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009; 360: 354-362
15. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol, 2005; 46: 1820-1826
16. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010; 303: 754-762
17. Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H: Determination of cutoff levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res, 2011; 128: e130-136
18. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V: Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res, 2007; 119: 277-284
19. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost, 2005; 3: 85-92
20. Schwarz UR, Geiger J, Walter U, Eigenthaler M: Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost, 1999; 82: 1145-1152
21. Kaneko M, Takafuta T, Cuyun-Lira O, Satoh K, Arai M, Yatomi Y, Ozaki Y: Evaluation of platelet function under high shear condition in the small-sized collagen bead column. J Lab Clin Med, 2005; 146: 64-75
22. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H: Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost, 2006; 4: 2490-2493
23. Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuss G, Katus H, Konstantinides S, Giannitsis E: Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J, 2010; 31: 1836-1844
24. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW: Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet, 1993; 2: 159-163
25. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephe nytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996; 60: 661-666
26. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T: Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J, 2009; 73: 1498-1503
27. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A: Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol, 2010; 55: 1139-1146
28. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation, 2008; 118: 1626-1636
29. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM, Topol EJ, Berger PB; the CHARISMA Investigators: Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation, 2009; 120: 2337-2344
30. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW: Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost, 2010; 8: 37-42
31. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937-944
32. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis. JAMA, 2010; 304: 1821-1830
33. Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H, Kozuki A, Inoue T, Hariki H, Hirata K: Impact of cytochrome P450 2C19* 2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2010; 75: 99-105
34. Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G: High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol, 2011; 57: 771-778
35. Kalantzi KI, Dimitriou AA, Milionis HJ, Goudevenos IA, Tselepis AD: Clopidogrel differentially affects plateletmediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost, 2011; 9: 875-878
36. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP: Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol, 2010; 33: 206-212
37. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S: Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2002; 23: 1771-1779
38. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J, 2006; 27: 2420-2425
39. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007; 369: 667-678
40. Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW: Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation, 2009; 119: 687-698
41. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K: Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation, 2009; 119: 987-995